Status:
COMPLETED
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
Lead Sponsor:
GlaxoSmithKline
Conditions:
Healthy Subjects
Depressive Disorder and Anxiety Disorders
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses. This study will use a medical...
Eligibility Criteria
Inclusion
- Healthy male subjects, aged 18-45 years Body weight \> 50 kg
- Non-Smoker
- Normal ECG, heart rate and blood pressure
Exclusion
- History of any cardiac disease
- History of regular alcohol consumption averaging \>14 drinks/week
- Current or recent gastrointestinal disease; History of psychiatric illness including any history of suicidal attempts
- Positive for Hepatitis B and C, and HIV.
- History of drug abuse.
- Exposure to research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden
- Family history of cancer (one or more first-degree relative diagnosed before the age of 55).
- Suffers from claustrophobia
- History or presence of neurological or psychiatric conditions
- Presence of a cardiac pacemaker or other implanted electronic device or metal implants
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00435695
Start Date
November 1 2006
End Date
December 1 2007
Last Update
June 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Toronto, Ontario, Canada, M5T 1R8